top of page

Pipeline

Transforming Known Biology into Breakthrough Medicines

We develop treatments for neurodegenerative diseases via an efficient clinical pathway.

9.jpg

Accelerating Development via De-Risked Strategy

Conventional drug discovery process

Discovery

Target

validation

Lead

optimization

Precinical

development

Phase 1

​clinical trial

Phase 2

​clinical trial

Phase 3

​clinical trial

FDA

application

Caren Pharma’s streamlined approach

FDA

application

FDA

application

​

Precinical

validation

Streamlined clinical program

FDA

application

Proprietary Formulations for Neurodegenerative Diseases

Pipeline

PROGRAM
CORRELATION
PRECLINICAL
CLINICAL PLANNING
CLINICAL PROGRAM
CP001M
CP002F

Mild Cognitive Impairment (Female)

CP003

Alzheimer's

CP004

Parkinson's

CP005

Multiple Sclerosis

CP006

Adult Depression

Mild Cognitive Impairment (Male)

bottom of page